KCK-based Cingulate hires a top legal officer as it enters the home stretch of its effort to win FDA approval for a new drug.

Cingulate’s Chairman and CEO Shane J. Schaffer expressed satisfaction with the FDA’s alignment with the company’s plans and thanked the agency for its guidance over the past seven years.

Cingulate (NASDAQ:CING – Get Free Report) had its target price lowered by equities research analysts at Ascendiant Capital Markets from $75.00 to $60.00 in a report released on Monday, Benzinga ...

July 2024 - Cingulate commissioned a managed care payor study in 2024 evaluating CTx-1301. The participants in the study represented over 121 million covered lives in the United States.

Fintel reports that on November 20, 2024, Maxim Group upgraded their outlook for Cingulate (NasdaqCM:CING) from Hold to Buy. Analyst Price Forecast Suggests 1,729.02% Upside As of October 22, 2024 ...

Maxim upgraded Cingulate (CING) to Buy from Hold with an $8 price target Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter ...

The target of their operations, the cingulate gyrus, is a thin ribbon of gray matter believed to play a role in human emotional states. The authors used a computer-guided technique known as ...

Cingulate begins the last study it needs to submit its leading drug candidate, a precision-timed release ADHD medication, for Food and Drug Administration approval.

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301 ...

Cingulate Inc. CING shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the announcement that ...

In addition to the European patent, Cingulate has patents in Australia, Canada and Israel, as well as pending patents in Hong Kong, the Republic of Korea, and the United States.